ChemicalBook > Product Catalog >API >Circulatory system drugs >Antihypertensive drugs >OMAPATRILAT

OMAPATRILAT

OMAPATRILAT Suppliers list
Company Name: Beijing HuaMeiHuLiBiological Chemical   
Tel: 010-56205725
Email: waley188@sohu.com
Company Name: MedChemexpress LLC  
Tel: 021-58955995
Email: sales@medchemexpress.cn
Company Name: Shanghai EFE Biological Technology Co., Ltd.  
Tel: 021-65675885 18964387627
Email: info@efebio.com
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 15026964105
Email: 2881489226@qq.com
Company Name: ShangHai Biochempartner Co.,Ltd  
Tel: 177-54423994 17754423994
Email: 2853530910@QQ.com

OMAPATRILAT manufacturers

  • Omapatrilat
  • Omapatrilat pictures
  • 2026-07-27
  • CAS:167305-00-2
  • Purity:
  • Supply Ability: 10g
OMAPATRILAT Basic information
Product Name:OMAPATRILAT
Synonyms:OMAPATRILAT;VANLEV;OMAPATRILAT/VANLEV;BMS 186716-01;7H-Pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid, octahydro-4-[[(2S)-2-mercapto-1-oxo-3-phenylpropyl]amino]-5-oxo-, (4S,7S,10aS)-;Omapatrilat >=98% (HPLC);Omapatrilat (BMS-186716)
CAS:167305-00-2
MF:C19H24N2O4S2
MW:408.53
EINECS:
Product Categories:
Mol File:167305-00-2.mol
OMAPATRILAT Structure
OMAPATRILAT Chemical Properties
Melting point 218-220°
alpha D -78.9° (c = 0.46 in DMF)
Boiling point 724.2±60.0 °C(Predicted)
density 1.37±0.1 g/cm3(Predicted)
storage temp. under inert gas (nitrogen or Argon) at 2-8°C
solubility DMSO: 30 mg/ml
form A crystalline solid
pka3.44±0.40(Predicted)
color White to gray
Safety Information
MSDS Information
OMAPATRILAT Usage And Synthesis
UsesTreatment of hypertension and congestive heart failure (neutral endopeptidase and angiotensin converting enzyme inhibitor).
DefinitionChEBI: Omapatrilat is a dipeptide.
in vivo

Omapatrilat demonstrates excellent blood pressure lowering in a variety of animal models characterized by various levels of plasma renin activity and significantly potentiates urinary sodium, ANP, and cGMP excretion in a cynomolgus monkey assay. Omapatrilat decreases mean arterial pressure (MAP) approximately 40 mmHg below baseline from 10 to 24 h. Oral administration of omapatrilat at 100 μM/kg once daily results in a 38 mmHg decrease in systolic blood pressure at day three as compared to vehicle [2]. Omapatrilat is widely used in experimental protocols related to hypertension and heart failure. Chronic oral administration of omapatrilat reduces aortic leakiness and atheroma formation with enhanced endothelial independent vasorelaxation to ANP[3]. Omapatrilat causes significant inhibition of plasma ACE and increased plasma renin activity in rats[4].

OMAPATRILAT Preparation Products And Raw materials
Tag:OMAPATRILAT(167305-00-2) Related Product Information
1-Ethyl-piperidine-2-carboxylic acid hydrochloride 1-Acetyl-2-piperidinecarboxylic acid CHEMBRDG-BB 4015189 AKOS BC-0095 CHEMBRDG-BB 4011096 2-(dibutylamino)acetic acid OMAPATRILAT